Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change?

Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.